StockNews.com cut shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) from a hold rating to a sell rating in a report published on Tuesday morning. Separately, Piper Sandler dropped their price objective on shares of Syros Pharmaceuticals from $11.00 to $7.00 and set an overweight rating on the stock in a research report on Tuesday, […]
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) insider David Roth sold 6,287 shares of Syros Pharmaceuticals stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $3.95, for a total value of $24,833.65. Following the completion of the transaction, the insider now directly owns 6,287 shares of […]
By Oyin Adeoyin Syros Pharmaceuticals shares fell after the company cut more than one- third of its staff and said its chief executive will resign. The stock.
Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings. Analyst Ratings This is a summary of […]